ArticleThe oncologist2020

Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.

Lin Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.